Clinical Trials Browser

Phase 2/3 × Lenalidomide × Clear all

NCT07095452 2026-03-16

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2/3 Recruiting

Multiple Myeloma

NCT07428369 2026-02-23

LINKER-MM8

Phase 2/3 Not yet recruiting

Multiple Myeloma

NCT03759093 2023-09-06

CURATE.AI Optimized Modulation for Multiple Myeloma

Phase 2/3 Unknown

Multiple Myeloma

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2/3 Completed

111 enrolled 20 charts

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02145598 2019-01-16

GERMAIN

Phase 2/3 Terminated

Multiple Myeloma

NCT02419118 2017-11-07

DARA

Phase 2/3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00055562 2005-06-24

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Phase 2/3 Completed

Melanoma, Neoplasm Metastasis